Category Asia/Pacific

US Businesses Urge Obama To Stoke Trade War With India

The heads of seventeen United States industry associations, including the US Chamber of Commerce, today issued a letter to President Barack Obama alleging that the Indian government is engaging in discriminating policies against US exports and encouraging swift action by the US government. Among the concerns is the country's treatment of patents.

The Novartis Decision: A Tale Of Developing Countries, IP, And The Role Of The Judiciary

Ahmed Abdel Latif says of the Novartis case: The ruling is also a revealing tale about the changing role of developing countries in the global intellectual property landscape and the growing influence of the judiciary in these countries in the implementation of international intellectual property rules.

The Judgment In Novartis v. India: What The Supreme Court Of India Said

Following the Indian Supreme Court decision in Novartis AG v. Union of India, Prof. Frederick Abbott says, "the judgment is well-crafted, with close attention to the facts presented, and appears to take a balanced view of the matters brought before the Court."

Novartis Loses Patent Bid: Lessons From India’s 3(d) Experience

New Delhi - On 1 April, in a packed room in India’s Supreme Court, two judges - Justice Aftab Alam and Justice Ranjana Desai - delivered a verdict that has the potential to dramatically change the national and global conversation about patents and patients.

Singapore Reveals 10-Year Plan To Be Global IP Hub

The Government of Singapore today has revealed a set of initiatives it plans to implement over the next decade to further develop the country as an intellectual property hub.

Innovation, IPR Cooperation Among Top Priorities For BRICS

The trade ministers of Brazil, Russia, India, China and South Africa (BRICS) today concluded a framework for cooperation that includes innovation and intellectual property rights, but separately.

Global Pharma Companies See Battle For Survival In Pakistan

Lahore, Pakistan - Weak regulation of the local pharmaceutical industry in Pakistan, including non-enforcement of intellectual property rights and the absence of a simple and swift dispute resolution mechanism, have hit the country’s health sector badly, industry sources say.